3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
37
Paclitaxel
36
Carboplatin
31
Cyclophosphamide
22
Albumin-Bound Paclitaxel
20
atezolizumab
16
130-nm albumin-bound paclitaxel
16
Taxes
15
Doxorubicin
15
Cisplatin
13
Capecitabine
13
Nivolumab
10
Docetaxel
8
olaparib
7
Gemcitabine
6
Everolimus
6
talazoparib
5
durvalumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Bevacizumab
5
veliparib
4
spartalizumab
4
sacituzumab govitecan
4
pegfilgrastim
4
liposomal doxorubicin
4
eribulin
4
Specimen Handling
4
Immunoglobulin G
4
trilaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Triple Negative Breast Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts